Increasing demand for its services in the Asia-Pacific region has led PharmaVentures, a leading provider of specialist consultancy, advisory and intelligence services, to appoint Dr Robert Daniels as its dedicated Vice President for the region. Robert will be based in Sydney, Australia.
The Australian pharmaceutical/biotechnology deal making market alone has grown 300% faster than the global market-place over the past decade, and with many emerging opportunities throughout the rest of the region, this is an important target market for PharmaVentures.
Robert will be responsible for establishing a team based in the Asia-Pacific region focused on assisting life sciences companies grow their businesses through in- and out-licensing and merger and acquisition activities. Through its Head Office in the UK and its presence in the US, PharmaVentures is ideally positioned to facilitate such transactions both into and out of the Asia-Pacific region.
In addition, PharmaVentures has significant experience and expertise in technology and company valuations, due diligence, expert reports and opportunity evaluation. PharmaVentures has worked closely with investors in Europe and the US for over ten years. PharmaVentures hopes to leverage this experience in the Asia-Pacific region to work with investors towards the continued development of both the private and public life sciences investment markets.
Robert adds to PharmaVentures’ consultancy and transactions expertise with over 10 years of experience in establishing and managing life sciences businesses, from university spin-outs to listed companies. He has successfully negotiated a wide range of deals, including raising capital, in- and out- licensing, joint venture creation and management, and product development partnerships. Robert has a PhD in developmental genetics and a Masters in entrepreneurial business management, and has previously worked in the UK, Australia and Hong Kong.
Fintan Walton, CEO of PharmaVentures said; “The Asia Pacific presents a wealth of important opportunities for PharmaVentures and is a key component in our aggressive growth ambitions. We already have strong relationships with BioMelbourne and AusBiotech, and with Robert’s presence in the area, we look forward to strengthening and building on our existing contacts. Robert has an outstanding business track record and brings much expertise to PharmaVentures.”
– ends –